Mitochondrial delivery of mastoparan with transferrin liposomes equipped with a pH-sensitive fusogenic peptide for selective cancer therapy

Yamada, Yuma; Shinohara, Yasuo; Kakudo, Tomoyuki; Chaki, Shinji; Futaki, Shiroh; Kamiya, Hiroyuki; Harashima, Hideyoshi

doi:10.1016/j.ijpharm.2005.06.009

Cited by 85 publications

(36 citation statements)

References 9 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, cytochrome c was observed only in the cytosol fraction. These results indicate the clear advantages of Tf-GALA-L for cancer therapy (Yamada et al, 2005b). Similarly, if other types of mitochondriotoropic molecules such as MTS-or PTD-conjugated/fused ODN, peptides and proteins were to be encapsulated into Tf-GALA-L, the selective targeting of cells and intracellular trafficking (i.e.…”

mentioning

confidence: 65%

See 1 more Smart Citation

Mitochondrial drug delivery and mitochondrial disease therapy – An approach to liposome-based delivery targeted to mitochondria

et al. 2007

Self Cite

View full text Add to dashboard Cite

Recent progress in genetics and molecular biology has provided useful information regarding the molecular mechanisms associated with the mitochondrial diseases. Genetic approaches were initiated in the late 1980s to clarify the gene responsible for various mitochondrial diseases, and information concerning genetic mutations is currently used in the diagnosis of mitochondrial diseases. Moreover, it was also revealed that mitochondria play a central role in apoptosis, or programmed cell death, which is closely related to the loss of physiological functions of tissues. Therefore, drug therapies targeted to the mitochondria would be highly desirable. In spite of the huge amount of mechanism-based studies of mitochondrial diseases, effective therapies have not yet been established mainly because of the lack of an adequate delivery system. To date, numerous investigators have attempted to establish a mitochondrial drug delivery system. However, many problems remain to be overcome before a clinical application can be achieved. To fulfill a drug delivery targeted to mitochondria, we first need to establish a method to encapsulate various drugs, proteins, peptides, and genes into a drug carrier depending on their physical characteristics. Second, we need to target it to a specific cell. Finally, multi-processes of intracellular trafficking should be sophisticatedly regulated so as to release a drug carrier from the endosome to the cytosol, and thereafter to deliver to the mitochondria. In this review, we describe the current state of the development of mitochondrial drug delivery systems, and discuss the advantage and disadvantage of each system. Our current efforts to develop an efficient method for the packaging of macromolecules and regulating intracellular trafficking are also summarized.Furthermore, novel concept of "Regulation of intramitochondrial trafficking" is proposed herein as a future challenge to the development of a mitochondrial drug delivery system. Yamada, Y., et al 3 Keywords:Mitochondrial drug delivery; Mitochondrial protein therapy; Mitochondrial gene therapy; Transferrin and GALA system; multifunctional envelope-type nano device (MEND);Regulation of intramitochondrial trafficking. Yamada, Y., et al 4

show abstract

mentioning

confidence: 65%

“…In previous study, the cellular response to MP encapsulated Tf-GALA-L was compared with that of free MP (Yamada et al, 2005b). In the case of free MP, cytochrome c was released not only in the cytosol but also to the medium, indicating that the plasma membrane along with mitochondria was damaged by MP.…”

mentioning

confidence: 99%

Mitochondrial drug delivery and mitochondrial disease therapy – An approach to liposome-based delivery targeted to mitochondria

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mastoparan is a 14-amino acid α-helical cell penetrating peptide from the venom of Vespula lewisii wasp that has nocive effects on cell membranes (Saar et al 2005). Mastoparan shows antitumor activity against human erythroleukemia cells and melanoma (Yamada et al 2005). In the latter, tumor cell death occurs through an induce of programmed cell death by oxidative stress, which causes mitochondrial depolarization (de Azevedo et al 2015).…”

Section: Targeting Cancer Cells Using Natural Peptidesmentioning

confidence: 99%

Anticancer Peptides: Prospective Innovation in Cancer Therapy

Gaspar

Castanho

2016

Host Defense Peptides and Their Potential as Therapeutic Agents

View full text Add to dashboard Cite

Current cancer treatments require improvements in selectivity and efficacy. Surgery, radiation, and chemotherapy approaches result in patient's suffering over time due to the development of severe side-effects that simultaneously condition adherence to therapy. Biologically active peptides, in particular antimicrobial peptides (AMPs), are versatile molecules in terms of biological activities. The cytotoxic activities of several AMPs turn this group of molecules into an amazing pool of new templates for anticancer drug development. However, several unmet challenges limit application of peptides in cancer therapy. The mechanism(s) of action of the peptides need better description and understanding, and innovative targets have to be discovered and explored, facilitating drug design and development. In this chapter, we explore the natural occurring AMPs as potential new anticancer peptides (ACPs) for cancer prevention and treatment. Their modes of action, selectivity to tumor compared to normal cells, preferential targets, and applications, but also their weaknesses, are described and discussed.

show abstract

“…This liposome targeted cells having high expression of transferrin receptors, which mediate its internalization by endocytosis. Results have shown that the encapsulated mastoparan was able to release cytochrome c, indicating its potential as an anticancer agent (Yamada et al, 2005). Fujiwara and colleagues (2008) determined the structure of an anticancer molecule from Vespa simillima.…”

Section: Bee and Wasp Venoms And Toxinsmentioning

confidence: 99%